ORIC Pharmaceuticals, Inc.
240 East Grand Avenue
2nd Floor
South San Francisco, CA 94080
United States
650 388 5600
https://www.oricpharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 100
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Richard A. Heyman Ph.D. | Co-Founder, Independent Chairman & Member of Scientific Advisory Board | 93k | 無 | 1957 |
| Dr. Jacob M. Chacko M.B.A., M.D. | President, CEO & Director | 961k | 無 | 1979 |
| Mr. Dominic G. Piscitelli C.P.A., M.B.A. | Chief Financial Officer | 654.74k | 無 | 1975 |
| Dr. Pratik S. Multani M.D., M.S. | Chief Medical Officer | 715.22k | 無 | 1967 |
| Dr. Charles L. Sawyers B.A., M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board | 無 | 無 | 1959 |
| Dr. Scott W. Lowe Ph.D. | Co-Founder & Member of Scientific Advisory Board | 無 | 無 | 無 |
| Dr. Lori Sickels Friedman Ph.D. | Chief Scientific Officer | 無 | 無 | 1964 |
| Dr. Christian V. Kuhlen Esq., J.D., M.D. | General Counsel | 無 | 無 | 1973 |
| Mr. Daniel Iazzetti | VP & Head of People | 無 | 無 | 無 |
| Dr. Edna Chow Maneval | Senior Vice President of Clinical Development | 無 | 無 | 1960 |
描述
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
公司管治
截至 2024年4月1日 止，ORIC Pharmaceuticals, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：10；董事會：4；股東權利：8；現金賠償：9。
